哈药集团三精制药2005年半年度报告（节录）_医药资讯

财务资料1、主要会计数据和财务指标单位:元 币种:人民币主要会计数据本报告期末上年度期末本报告期末比上年度期末增减（％）调整后调整前流动资产1,326,014,339.26965,710,344.65965,710,344.6537.31流动负债790,519,148.91694,566,592.96694,566,592.9613.81总资产2,031,332,153.541,868,451,818.321,868,451,818.328.72股东权益（不含少数股东权益）648,396,655.33599,677,165.74599,677,165.748.12每股净资产1.681.551.558.38调整后的每股净资产1.661.541.547.79报告期（1－6月）上年同期本报告期比上年同期增减（％）调整后调整前净利润27,884,966.28-7,965,640.37-7,965,640.37不适用扣除非经常性损益后的净利润29,404,956.73-5,243,533.22-5,243,533.22不适用每股收益0.0721-0.0309-0.0309不适用净资产收益率（%）4.00-0.02-0.02增加4.02百分点经营活动产生的现金流量净额126,678,916.48-8,259,129.71-8,259,129.71不适用2、扣除非经常性损益项目和金额单位:元 币种:人民币非经常性损益项目金额处置除公司产品外的其他资产产生的损益841,225.37扣除资产减值准备后的其他各项营业外收入、支出-2,622,942.91所得税影响数261,727.09合计-1,519,990.453、净资产收益率及每股收单位:元 币种:人民币报告期利润净资产收益率（%）每股收益全面摊薄加权平均全面摊薄加权平均主营业务利润64.1967.821.07651.0765营业利润18.8919.960.31680.3168净利润4.304.540.07210.0721扣除非经常性损益后的净利润4.544.790.07610.07614、利润及利润分配表单位:元 币种:人民币项目合并母公司本期数上年同期数本期数上年同期数一、主营业务收入841,739,725.38236,199,588.0883,636.55236,199,588.08减：主营业务成本416,704,715.21184,531,702.1772,032.40184,531,702.17主营业务税金及附加8,858,265.212,926,206.720.002,926,206.72二、主营业务利润（亏损以“-”号填列）416,176,744.9648,741,679.1911,604.1548,741,679.19加：其他业务利润（亏损以“-”号填列）782,123.78-984,809.400.00-1,003,089.40减:营业费用206,162,717.4213,147,625.380.0013,147,625.38管理费用85,306,616.3342,112,529.211,187,176.5541,835,341.25财务费用3,029,258.095,959,126.541,078,842.715,959,273.30三、营业利润（亏损以“-”号填列）122,460,276.90-13,462,411.34-2,254,415.11-13,203,650.14加：投资收益（损失以“-”号填列）-25,543,367.8730,020,867.89-258,761.20补贴收入0.008,218,878.120.008,218,878.12营业外收入889,453.92749,347.990.00749,347.99减：营业外支出2,671,171.463,471,455.140.003,471,455.14四、利润总额（亏损总额以“-”号填列）95,135,191.49-7,965,640.3727,766,452.78-7,965,640.37减：所得税23,352,826.500.00减：少数股东损益43,897,398.710.00加：未确认投资损失(合并报表填列)五、净利润（亏损以“-”号填列）27,884,966.28-7,965,640.3727,766,452.78-7,965,640.37加：年初未分配利润79,575,716.6966,068,337.0882,183,692.3766,068,337.08其他转入0.000.00六、可供分配的利润107,460,682.9758,102,696.71109,950,145.1558,102,696.71减：提取法定盈余公积0.000.00提取法定公益金0.000.00提取职工奖励及福利基金(合并报表填列)0.000.00提取储备基金0.000.00提取企业发展基金0.000.00利润归还投资0.000.00七、可供股东分配的利润107,460,682.9758,102,696.71109,950,145.1558,102,696.71减：应付优先股股利0.000.00提取任意盈余公积0.000.00应付普通股股利7,731,847.967,731,847.96转作股本的普通股股利0.000.00八、未分配利润(未弥补亏损以“-”号填列)99,728,835.0158,102,696.71102,218,297.1958,102,696.71补充资料：1.出售、处置部门或被投资单位所得收益2.自然灾害发生的损失3.会计政策变更增加(或减少)利润总额4.会计估计变更增加(或减少)利润总额5.债务重组损失6.其他 详见《哈药集团三精制药股份有限公司2005年半年度报告》（据“上海证券交易所”；医药网整理，严禁转载） 医药网新闻